If our hypothesis was proven, SNS antagonism with PRL as a novel, early, pro-regenerative treatment for NAFLD and potentially other liver diseases could easily be translated to the clinic because of the vast experience with this and other β-adrenoceptor antagonists and their low cost compared to putative cytokine or cell based therapies. This evidence concerns the gene PRL and metabolic dysfunction-associated steatotic liver disease.